Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Ave, Ottawa, Ontario, CanadaK1S 5S8.
Int J Technol Assess Health Care. 2021 Jan 22;37:e19. doi: 10.1017/S0266462320002251.
In recognition of patients' roles using, and contributing to, a publicly funded health system, the Canadian Agency for Drugs and Technologies in Health (CADTH) created a Patient and Community Advisory Committee. Twelve members bring lived experiences of chronic illness, progressive illness, mental illness, trauma, traveling long distances for treatment, and caregiving to an ill child, parent, or spouse. Members contribute their own insights and ideas but do not represent specific organizations or viewpoints. This paper explores how CADTH determined the committee's role, whether to have individuals or organizations as members, and how to recruit for diversity. The creation of this committee is changing how CADTH engages with patients.
为了认可患者在使用和参与公共资助的卫生系统方面所扮演的角色,加拿大药品和技术评估署(CADTH)成立了一个患者和社区咨询委员会。该委员会的 12 名成员具有慢性病、进行性疾病、精神疾病、创伤、长途跋涉求医和照顾患病儿童、父母或配偶的经历。成员们贡献了自己的见解和想法,但不代表特定的组织或观点。本文探讨了 CADTH 如何确定委员会的角色、是由个人还是组织担任成员,以及如何进行多样性招募。该委员会的成立正在改变 CADTH 与患者互动的方式。